Wellbeing Guide For Hormone Optimization & Metabolic Health

Discover how a clinical approach to hormone optimization can enhance your metabolic health and overall wellness.

Abstract

In this educational post, I present a clinician-focused, first-person synthesis of modern, evidence-based hormone optimization and systems biology. I integrate the latest findings from leading researchers with my clinical observations to explain how estrogen, testosterone, and progesterone regulate brain, bone, cardiovascular, metabolic, immune, and sexual health. I clarify why bioidentical 17β-estradiol and micronized progesterone differ from synthetic formulations, detail the importance of route, dose, and timing, and review metabolite safety and the gut microbiome’s influence on hormone signaling. I also outline protocols for dosing, delivery modality selection, and monitoring, and provide a systems-based framework for managing risks, side effects, and complications. My goal is to help clinicians and patients understand the mechanisms, translate research into practice, and pursue preventive, physiologic care that improves quality of life and longevity.
Keywords: hormone optimization, estrogen therapy, testosterone therapy, progesterone benefits, bioidentical hormones, transdeestradioladiol, micronized progesterone, androgen receptor, estrogen receptor, estrogen metabolites, COMT, methylation, estrobolome, microbiome, β-glucuronidase, bile acids, insulin sensitivity, bone density, cardiovascular risk, neurosteroids, sleep, erythrocytosis, prostate monitoring, VTE risk, functional medicine, clinical protocols, dosing strategies, side effect management

My Purpose and Preventive Care Perspective

As a clinician trained in functional and integrative medicine, I learned early in my career in urgent care and through exposure to end-of-life care that many emergencies arise from chronic, modifiable diseases. That realization pushed me toward proactive medicine grounded in hormone optimization and systems biology. Today, I combine peer-reviewed research with day-to-day practice insights from El Paso and beyond to deliver precise, safe, and personalized care.
I prioritize evidence-based protocols that restore physiologic ranges, avoiding supraphysiologic exposures that raise risk.
I use mechanism-first reasoning, tracing receptor pharmacology, downstream signaling, metabolic clearance, and tissue-specific effects to guide decisions.
I integrate gut and nutrient strategies to improve receptor sensitivity, metabolite profiles, and clinical outcomes.
Explore my ongoing clinical updates and case-informed reflections:

• https://chiromed.com/
• https://www.linkedin.com/in/dralexjimenez/

Why Mechanisms and Literature Must Drive Hormone Care

Persistent misconceptions around cancer risk, cardiometabolic outcomes, and the idea that “all hormones are the same” still influence practice. To correct these, I synthesize high-impact literature and apply physiology.
Core principle: the preventive value of hormones is context-dependent. Risks increase when the dose, delivery route, or metabolism are mismatched with patient physiology, or when monitoring is inadequate (NAMS Position Statement, 2022).
Clinical behavior:
Stratify baseline risk (family history, genomics, comorbidities).
Optimize metabolic and inflammatory terrain.
Select the lowest effective dose that restores function and quality of life while meeting biomarker targets.
This systems-first approach allows genuine prevention rather than symptom suppression.

Estrogen Optimization and Disease Prevention: Molecule, Receptor, and Route

Estrogen is not estradiol (E2), estrone (E1), or estriol (E3); these interconvert and signal via ERα, ERβ, and non-genomic pathways. These distinctions drive outcomes across organ systems.
Cardiometabolic: Estradiol improves endothelial nitric oxide synthase, dampens vascular inflammation, and influences lipoprotein profiles. Loss of E2 after menopause increases arterial stiffness and atherogenesis (Rosano et al., Endothelial effects of estrogen, 2007; Manson et al., WHI outcomes, 2013).
Skeletal: Estrogen reduces osteoclastogenesis via RANKL/OPG and supports osteoblast survival, lowering bone turnover and fracture risk (NAMS Position Statement, 2022).
Neurocognitive: E2 enhances synaptic plasticity, glucose utilization, and mitochondrial biogenesis, with neurosteroid effects modulating GABAergic tone (Brinton, Estrogen-induced plasticity, 2008; Arevalo et al., Estradiol and progesterone modulate brain inflammation, 2015).
Immune and repair: ER signaling tempers NF-κB, influences Treg activity, and supports tissue repair (Arevalo et al., 2015).

Cancer Risk, Metabolites, and Delivery

The question is not “Do hormones cause cancer?” but Whichh hormone, at what dose, via what route, in which patient, with what metabolism?””
Metabolite pathways:
2-hydroxylated estrogens are generally less proliferative.
4-hydroxylated estrogens can form catechol quinones with genotoxic potential.
16α-hydroxylated estrogens carry proliferative signals.
Favoring 2-hydroxylation and enhancing COMT-mediated methylation reduces reactive metabolite burden (Estrogen metabolites and breast cancer risk, 2012; COMT polymorphisms and cancer risk, 2004).
Route matters: Transdermal estradiol avoids hepatic first-pass induction of clotting factors and triglycerides, reducing VTE and metabolic risks compared with oral estrogens (Transdermal vs oral estrogen and vascular risk, 2016; Scarabin, Oral vs transdermal estrogen and VTE, 2003).
Progestogen pairing:
Endometrial protection requires progesterone or a progestin for women with a uterus.
Bioidentical micronized progesterone has more favorable vascular and breast profiles than certain synthetic progestins (Stanczyk et al., Progestins vs progesterone, 2013).

Clinical Protocol Logic

Start low, titrate slowly, and aim for physiologic mid-reference ranges aligned with symptom relief and biomarkers.
Prefer transdeestradiol in higher-risk or migraine-with-aura patients.
Monestradioladiol, estrone, SHBG, TSH, lipids, CRP, and urinary estrogen metabolites when indicated.
Support metabolite safety:
Dietary indoles (crucifers), omega-3s, glycine, and methyl donors as appropriate.
Clinical observation: In active women with estradiol and recurrent stress fractures, transdermal E2 combined with micronized progesterone and targeted micronutrients (calcium, vitamin D3/K2, magnesium, omega-3s) improves bone turnover markers, recovery, and mood. Adding resistance training amplifies skeletal benefits and helps with weight management. See practice insights at https://chiromed.com/ and https://www.linkedin.com/in/dralexjimenez/.

Testosterone: Anabolism, Metabolism, and Modality Selection

Testosterone reaches beyond muscle to influence erythropoiesis, insulin sensitivity, libido, bone density, mood, and immune tone. Age-related decline intersects with rising SHBG, sleep disruption, adiposity, and inflammation.
Androgen receptor dynamics:
Testosterone signals through the AR, with the balance between coactivators and corepressors affecting tissue outcomes.
Adiposity increases aromatase activity, shifting testosterone toward estradiol and altering feedback loops.
Metabolites:
Conversion to DHT via 5α-reductase impacts prostate, skin, and hair.
Peripheral conversion to E2 is essential for the bone and the brain.
Cardiometabolic:
Physiologic testosterone improves visceral adiposity, HbA1c, and triglycerides; supraphysiologic dosing increases the risk of erythrocytosis and adverse lipid profiles (Endocrine Society Guideline, 2018).

Delivery Modalities

Transdermal gels/creams: steady exposure, titration flexibility; educate on contact transfer precautions.
Injectable (e.g., cypionate): weekly or twice-weekly dosing reduces peaks and troughs affecting mood and hematology.
Subcutaneous pellets: extended release with adherence advantages; less flexible titration.
Oral undecanoate: lymphatic absorption; variable exposures.

Monitoring and Mitigation

Track total/free testosterone, Sestradioladiol, hematocrit/hemoglobin, PSA, lipids, LFTs.
Manage aromatization:
Use body composition interventions first.
Avoid routine use of aromatase inhibitors (AIs) to prevent bone and mood-related adverse effects; use only when clearly indicated.
Address erythrocytosis:
Dose-adjust; increase dosing frequency; evaluate for sleep apnea; consider phlebotomy when necessary.
Clinical observation: Men with obesity and sleep apnea respond best when CPAP adherence and resistance/interval training precede or accompany testosterone. This reduces the need for doses, stabilizes hematocrit, and improves glycemia. For peak–trough irritability, twice-weekly subcutaneous injections improve tolerability. Professional reflections shared at https://chiromed.com/ and https://www.linkedin.com/in/dralexjimenez/.

Progesterone: Neurosteroid, Sleep Modulator, and Endometrial Protector

Progesterone is a critical neurosteroid that enhances GABA-A activity, stabilizes mood and sleep, and orchestrates endometrial differentiation to oppose estrogen-driven proliferation.
Why bioidentical micronized progesterone:
CNS benefits via allopregnanolone improve sleep initiation and anxiety more consistently than some progestins.
Favorable metabolic effects on lipids and blood pressure compared to certain synthetic analogs.
Essential endometrial protection in women receiving systemic estrogen (Micronized progesterone pharmacology, 2019).
Dosing strategy:
Night dosing aligns with sedative neurosteroid effects.
In perimenopause, cyclic or continuous regimens tailored to symptoms and bleeding.
Adjust dose/route for mastalgia or fluid retention and reassess estrogen dosing and metabolites.
Clinical observation: In perimenopausal patients with sleep maintenance insomnia, nighttime micronized progesterone often reduces awakenings within 1–2 weeks. Combined with sleep hygiene and light therapy, the benefits are durable and reduce reliance on sedative-hypnotics.

Gut Health and the Estrobolome: Amplifying Hormone Receptor Activity

Hormones are effective only within a healthy terrain. The gut microbiome—especially the estrobolome—shapes estrogen recirculation, clearance, and receptor engagement.
Mechanistic links:
β-Glucuronidase excess deconjugates estrogens, driving enterohepatic recirculation and elevating certain metabolites.
Bile acid signaling via FXR and TGR5 intersects with glucose and lipid metabolism, affecting hormone sensitivity.
Barrier integrity: Increased permeability raises LPS levels, provoking TNF-α/IL-6, which can blunt hormone receptor signaling (The estrobolome and women’s health, 2019; Microbiome, bile acids, and metabolic regulation, 2014).
Clinical tools:
Diet emphasizing fiber, polyphenols, and fermented foods to diversify microbiota and modulate β-glucuronidase.
Targeted probiotics with bile salt hydrolase activity when indicated.
Consider calcium D-glucarate for high β-glucuronidase levels while addressing the root causes of diet/dysbiosis.
Support phase II detoxification with glycine, sulfur amino acids, and methyl donors.
Clinical observation: In estrogen-dominant symptom patterns with persistent mastalgia, correcting constipation, optimizing fiber/water intake, and addressing dysbiosis normalizes transit and reduces symptoms within 4–6 weeks, enabling lower hormone doses with better tolerability.

Nutrient Cofactors: Steroidogenesis, Metabolism, and Receptor Sensitivity

Robust hormone therapy requires nutrient sufficiency to support synthesis and clearance.
Zinc: Cofactor for 3β-HSD and 5α-reductase modulation; supports AR function.
Magnesium: Required for ATP-dependent enzymes in steroidogenesis and for insulin sensitivity, which influences SHBG and bioavailable hormones.
Vitamin D: Through VDR, modulates aromatase and immune tone; sufficiency enhances musculoskeletal responses to hormones (Vitamin D and testosterone interplay, 2019).
B vitamins (B2, B6, B12, folate): Support methylation and COMT for catechol estrogen clearance.
Omega-3 fatty acids: Reduce inflammatory tone, improving endothelial and receptor signaling (Omega-3s and endothelial function, 2014).
Choline and glycine: Facilitate phase II conjugation and bile acid metabolism.
Clinical observation: Correcting magnesium deficiency attenuates PVCs and improves sleep in patients starting progesterone. Addressing vitamin D insufficiency improves muscle strength responses to testosterone in older adults.

Finding Hormonal Harmony- Video

Choosing and Managing Hormone Delivery Modalities

Selecting a modality balances pharmacokinetics, safety, lifestyle, and monitoring.
Estrogen modalities:
Transdermal patches/gels: predictable PK, lower VTE risk; patches improve adherence; gels allow fine titration.
estradiol: consider only when benefits outweigh hepatic effects; monitor triglycerides and clotting risk.
Vaginal estradiol/estriol: local therapy for genitourinary syndrome; minimal systemic absorption at low doses.
Progesterone modalities:
Oral micronized progesterone: best for sleep and endometrial protection; take with a small fat-containing snack.
Vaginal progesterone: useful for uterine-focused effects or GI sensitivity.
Levonorgestrel IUD: potent endometrial suppression; useful for bleeding control with systemic estrogen.
Testosterone modalities:
Topical: cautious initiation and fine-tuning; emphasize site precautions.
Injectable: weekly/twice-weekly subcutaneous improves stability; counsel on technique.
Pellets: consider for adherence barriers; anticipate minor surgical risks and less flexible adjustments.
Monitoring cadence: baseline labs; recheck at 6–8 weeks after initiation or change; then every 3–6 months once stable; tailored to risk and symptom trajectory.

Safety, Side Effects, and Complication Management

Every protocol needs a safety net.
VTE risk: Favor transdermal estradiol; address obesity, immobility, smoking; consider thrombophilia screening when history suggests (Transdermal vs oral estrogen and vascular risk, 2016).
Breast health: Use the lowest effective estrogen dose with micronized progesterone; personalize imaging cadence and assess family history; emphasize exercise and alcohol moderation (Chlebowski et al., WHI breast cancer follow-up, 2020).
Prostate: In men, baseline PSA and DRE per guidelines; avoid initiating in untreated high-risk contexts; recheck PSA after stabilization (Endocrine Society Guideline, 2018).
Erythrocytosis: Adjust testosterone, check sleep apnea, ensure hydration; use phlebotomy only when clinically necessary (Sleep apnea and erythrocytosis, 2012).
Mood changes: Avoid sharp injection peaks; consider the topical route or adjust the frequency; evaluate sleep and micronutrient status.
Abnormal uterine bleeding: Verify endometrial protection, evaluate dosing, consider ultrasound; rule out structural causes.
Acne/hirsutism: Dose-adjust and assess DHT; consider 5α-reductase modulation case-by-case and discuss fertility.
Clinical observation: The highest-risk side effects occur when therapy starts without adequate risk stratification or when dose escalation outruns monitoring. Most complications abate with dose correction, route change, and terrain optimization.

Integrating Lifestyle, Behavior, and Shared Decision-Making

Hormones amplify what lifestyle initiates. Without sleep consolidation, resistance training, cardiorespiratory fitness, and nutritional adequacy, hormone therapy underperforms.
Exercise:
Resistance training enhances bone mineral density and insulin sensitivity.
Aerobic work improves endothelial function.
Both attenuate aromatase via fat loss (Exercise and bone metabolism, 2020).
Nutrition:
Adequate protein, fiber, and phytonutrient diversity support the microbiome and detox pathways.
Alcohol moderation reduces estrogenic load and breast risk.
Stress regulation:
Elevated cortisol undermines sex steroid signaling; mind–body practices and sleep hygiene are essential.
I emphasize shared decision-making, present risks and benefits with data, and align plans with patient values. Education transforms adherence and safety.

Practical Algorithm: Putting It All Together

Evaluate baseline: history, goals, cancer/prostate/VTE risk, sleep, mood, cardiometabolic markers, body composition, GI function.
Correct terrain: sleep, nutrition, movement, microbiome support, micronutrient deficits.
Select modality: choose delivery route aligned with risk; start low and titrate based on symptoms and labs.
Support metabolism: use diet and targeted supplements; monitor estrogen metabolites when indicated.
Monitor and adjust: schedule labs and visits; use symptom scores; adjust dose/frequency/route to sustain physiologic targets.
Prevent and manage side effects: anticipate, educate, and intervene early; document shared decisions and outcomes.

EEstrogen’sCritical Window, WHI Misconceptions, and Modern Guidelines

The Women’s Health Initiative (WHI) used conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA), not bioidentical molecules. Early risk signals were concentrated in the progestin arm, yet headlines generalized these findings to all hormones (Manson et al., WHI outcomes, 2013). Subsequent analyses demonstrated nuance:
Estrogen-alone in hysterectomized women showed neutral to beneficial patterns for some endpoints, including breast cancer incidence and mortality (Chlebowski et al., 2020).
The critical window hypothesis supports starting therapy near menopause to optimize vascular and neuroprotective effects (Maki & Henderson, Critical window, 2016).
Modern guidance emphasizes individualization, rejects routine discontinuation at age 65, and supports continuation when risk–benefit is favorable (NAMS 2017 Position Statement, 2017; NAMS 2022 Update, 2022; ACOG Practice Bulletin, 2023).
My practice aligns with these updates by prioritizing bioidentical 17β-estradiol and micronized progesterone, favoring transdermal routes, and personalizing plans.

Estradiol, Cardiovascular and Brain Protection, and Discontinuation Risks

A body of evidence indicates that appropriately destradioladiol improves vascular and metabolic health, reduces events, and supports neuroprotection:
Endothelial benefits via NO synthase activation, reduced NF-κB, improved lipids, and plaque stability (Mendelsohn & Karas, Cardiovascular effects of estrogen, 2005).
Neuroprotection through PI3K/Akt, ERK, BBB integrity preservation, and microglial modulation (Liu et al., Estradiol neuroprotection, 2007; Arevalo et al., 2015).
Abrupt estrogen withdrawal increases cardiac and stroke risks due to autonomic destabilization, vascular tone shifts, and coagulation changes; tapering is safer (Grodstein et al., HT discontinuation CV implications, 2003).
In practice, I counsel patients on continuity and, when needed, careful tapering, while maintaining protective lifestyle interventions.

Testosterone–Estradiol Synergy and Avoiding Aromatase Inhibitors in Men

Estradiol and testosterone synergize to improve lipids, insulin, and visceral fat. Routine AI use can blunt these benefits:
Bisphenol A raises pain sensitivity, worsens metabolic parameters, and undermines bone health (Henry et al., AI musculoskeletal symptoms, 2018; Handelsman, Estrogen in men’s bone health, 2013).
Allowing physiological aromatization supports the integrity of the brain, bone, vascular, and metabolic systems.
I avoid routine AIs, monestradioladiol rather than preemptively blocking it, and use body composition strategies to modulate aromatization.

Sexual Health, Genitourinary Support, and MMen’sEstrogen Balance

Estrogen influences libido, arousal, vaginal mucosa, pelvic floor, and urogenital health. In men, balaestradiol supports libido, endothelium, and bone. I pair estradiol with local therapies (e.g., vagestradiol or DHEA) and pelvic rehab when indicated, while ensuring mmen’sE2/T ratios remain physiological.

My Clinical Observations: Translating Research into Outcomes

From my practice at Chiromed and collaborative care settings:
Women initiating transdermal 17β-estradiol near menopause report rapid improvements in cognition, sleep, and vasomotor symptoms; over 6–12 months, we see improvements in lipids, lower CRP, and better glycemic metrics with nutrition and resistance training.
Adding micronized progesterone stabilizes mood and sleep; patients report deeper, more restorative rest.
Thoughtful androgen support in women can enhance energy, bone, and sexual desire; monitoring hair/skin/lipids guides dosing.
Chronic pain patients often exhibit hormonal insufficiency; corticosteroids and progesterone reduce central sensitization; when combined with myofascial care, strength training, and anti-inflammatory nutrition, outcomes improve.
Deprescribing occurs naturally: fewer sedatives as sleep normalizes, reduced antidepressants with neurosteroid support, lower antihypertensives as endothelial function and autonomic tone improve.
Explore my clinical insights:
https://chiromed.com/
https://www.linkedin.com/in/dralexjimenez/

Practical Protocol Considerations and Rationale

I design protocols to match physiology, goals, and safety:
Comprehensive assessment:
Menstrual history, vasomotor symptoms, cognition, mood, sexual health, fracture risk, cardiometabolic markers, and family history.
Estradiol:
Initiate transdermal 17β-estradiol for brain, vascular, and bone signaling due to receptor congruence and lower thrombotic risk.
Progesterone:
Add oral micronized progesterone for uterine protection and neurocalm; avoid progestins due to their receptor promiscuity and immune effects.
Androgens:
Consider low-dose testosterone in women for bone, muscle, and libido with careful monitoring; in men, maintain physiologic dosing and avoid routine AIs.
Lifestyle medicine:
Progressive resistance training, zone-2 cardio, sleep optimization, stress management, and a phytonutrient-rich diet.
Gut–hormone axis:
Address dysbiosis, increase fiber and polyphenol intake, support liver detoxification, and normalize enterohepatic cycling.
Monitoring:
Track symptoms, vitals, lipids, CRP, glucose/insulin, DEXA, endometrial status, and cognitive screening as needed.
Each element is chosen to advance patient goals and respect biological signaling.

Myths and Misconceptions Corrected

““strogen causes breast cancer.””Evidence differentiates molecules: risks increased with progestin combinations started late in WHI; estrogen-alone data show neutral/beneficial patterns in specific groups. Bioidentestradiol with progesterone is distinct from CEE+MPA (Chlebowski et al., 2020; NAMS 2022 Update, 2022).
“”ll hormones are the same.””False. 17β-estradiol and micronized progesterone are physiologically coherent; synthetic analogs have different receptor promiscuity and effects (Stanczyk et al., 2013).
“top at 65.” Not evidence-based; discontinuation reverses gains. Continuation should be individualized (NAMS 2017 Position Statement, 2017; NAMS 2022 Update, 2022).
“Only treat hot flashes.””Estrogen is a longevity hormone that affects the brain, bones, heart, immune system, and sexual health.

Conclusion: Modern, Evidence-Based Hormone Optimization

Estrogen, specifically 17β-estradiol, paired with micronized progesterone, and testosterone where appropriate, supports neuroprotection, bone strength, cardiovascular resilience, immune modulation, and sexual vitality. Outcomes depend on molecule, route, dose, timing, and systemic context. By embracing modern evidence and systems biology, we can reduce polypharmacy, elevate quality of life, and practice true preventive medicine.

References

• Menopausal hormone therapy and long-term health outcomes (NAMS Position Statement). (2022). The Journal of Clinical Endocrinology & Metabolism.
• The 2017 hormone therapy position statement of The North American Menopause Society (NAMS). (2017).
• ACOG Practice Bulletin: Management of Menopausal Symptoms. (2023).
• Transdermal versus oral estrogen therapy and vascular risk. (2016). Circulation.
• Oral vs transdermal estrogen and venous thromboembolism risk. (2003). The Lancet.
• Estrogen metabolites and breast cancer risk: 2-hydroxylation versus 16α-hydroxylation balance. (2012). Cancer Epidemiology, Biomarkers & Prevention.
• COMT polymorphisms, catechol estrogens, and cancer risk. (2004). Carcinogenesis.
• Estradiol and progesterone modulate brain inflammation through their respective receptors. (2015). Journal of Neuroendocrinology.
• Endothelial effects of estrogen: atherosclerosis and beyond. (2007). Current Opinion in Cardiology.
• Menopausal hormone therapy and health outcomes during WHI intervention and extended poststopping phases. (2013). JAMA.
• Hormone therapy and abrupt discontinuation: Cardiovascular implications. (2003). Circulation.
• Micronized progesterone: pharmacology and clinical implications. (2019). The Journal of Clinical Endocrinology & Metabolism.
• The estrobolome and its influence on women’s health. (2019). Nature Reviews Endocrinology.
• Microbiome, bile acids, and metabolic regulation. (2014). Nature Reviews Microbiology.
• Sleep apnea, testosterone therapy, and erythrocytosis. (2012). Journal of Sleep Research.
• Exercise and bone metabolism with hormone therapy. (2020). Osteoporosis International.
• Omega-3 fatty acids, inflammation, and endothelial function. (2014). Arteriosclerosis, Thrombosis, and Vascular Biology.
• Vitamin D and testosterone interplay in muscle. (2019). Sports Medicine.
• Endocrine Society Clinical Practice Guideline: Testosterone therapy in men with hypogonadism. (2018). The Journal of Clinical Endocrinology & Metabolism.
• Association of menopausal hormone therapy with breast cancer incidence and mortality (WHI long-term follow-up). (2020). JAMA Internal Medicine.

About Dr. Alexander Jimenez

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, provides integrative, functional, and evidence-based musculoskeletal and metabolic care. Clinical insights and educational resources are available at:
https://chiromed.com/
https://www.linkedin.com/in/dralexjimenez/

Keywords

hormone optimization, estrogen therapy, testosterone therapy, progesterone benefits, bioidentical hormones, transdeestradioladiol, micronized progesterone, androgen receptor, estrogen receptor, estrogen metabolites, COMT, methylation, estrobolome, microbiome, β-glucuronidase, bile acids, insulin sensitivity, bone density, cardiovascular risk, neurosteroids, sleep, erythrocytosis, prostate monitoring, VTE risk, functional medicine, clinical protocols, dosing strategies, side effect management, longevity, preventive medicine

Disclaimer

This educational content is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication or therapy without consulting your qualified healthcare provider.

SEO tags: hormone optimization, bioidentestradiol, micronized progesterone, transdermal estrogen safety, testosterone therapy men, aromatase inhibitors risks, menopause brain health, dementia prevention estrogen, cardiovascular endothelial function estrogen, bone density menopause therapy, estrobolome gut hormones, functional medicine hormone therapy, VTE risk transdermal estrogen, progesterone neurosteroid sleep, erythrocytosis testosterone management, Dr. Alexander Jimenez DC APRN FNP-BC, evidence-based endocrinology, WHI misconceptions and modern guidelines, NAMS hormone therapy position, androgen therapy women, deprescribing with hormone optimization